Authors: Sanchez, Katherine; Kim, Isaac; Chun, Brie; Pucilowska, Joanna; Redmond, William L.; Urba, Walter J.; Martel, Maritza; Wu, Yaping; Campbell, Mary; Sun, Zhaoyu; Grunkemeier, Gary; Chang, Shu Ching; Bernard, Brady; Page, David B.
Online: https://doi.org/10.1186/s13058-020-01378-4
Issue: Breast Cancer Res. 2021 Jan 7;23(1):2.
Abstract
The H&E stromal tumor-infiltrating lymphocyte (sTIL) score and programmed death ligand 1 (PD-L1) SP142 immunohistochemistry assay are prognostic and predictive in early-stage breast cancer, but are operator-dependent and may have insufficient precision to characterize dynamic changes in sTILs/PD-L1 in the context of clinical research. We illustrate how multiplex immunofluorescence (mIF) combined with statistical modeling can be used to precisely estimate dynamic changes in sTIL score, PD-L1 expression, and other immune variables from a single paraffin-embedded slide, thus enabling comprehensive characterization of activity of novel immunotherapy agents.
